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Abstract
Lithium, a drug that has long been used to treat bipolar disorder and some other human pathogenesis, has
recently been shown to stimulate neural precursor growth. However, the involved mechanism is not clear. Here,
we show that lithium induces proliferation but not survival of neural precursor cells. Mechanistic studies suggest
that the effect of lithium mainly involved activation of the transcription factor NF-AT and specific induction of a
subset of proliferation-related genes. While NF-AT inactivation by specific inhibition of its upstream activator
calcineurin antagonized the effect of lithium on the proliferation of neural precursor cells, specific inhibition of the
NF-AT inhibitor GSK-3b, similar to lithium treatment, promoted neural precursor cell proliferation. One important
function of lithium appeared to increase inhibitory phosphorylation of GSK-3b, leading to GSK-3b suppression and
subsequent NF-AT activation. Moreover, lithium-induced proliferation of neural precursor cells was independent of
its role in inositol depletion. These findings not only provide mechanistic insights into the clinical effects of lithium,
but also suggest an alternative therapeutic strategy for bipolar disorder and other neural diseases by targeting the
non-canonical GSK-3b-NF-AT signaling.
Introduction
Lithium is a monovalent cation belonging to the group
of alkali metals. It has been the reference standard med-
ication for acute and prophylactic treatment of bipolar
disorder/manic depressive illness, a brain disorder in
which normal moods alternate with both depression and
mania, which is recognized by the World Health Orga-
nization as a leading debilitating neuropsychiatric disor-
der that affects about 1.3% of both sexes globally [1].
Recent animal studies suggest a beneficial effect of
lithium on other central nervous system (CNS) diseases,
such as brain ischemia, spinal cord injury, Alzheimer’s
disease and Huntington’s disease [2].
Currently, two major targets of lithium are suggested
responsible for the actions of lithium on bipolar disorder
and other CNS diseases: inositol depletion and glycogen
synthase kinase 3b (GSK-3b) inhibition. Lithium inhibits
inositol polyphosphate 1-phosphatase (IPPase) and inositol
monophosphate phosphatase (IMPase), two enzymes criti-
cal for the recycling and de novo synthesis of inositol,
thereby leading to inositol depletion [3]. Lithium may also
reduce inositol uptake from outside of cells by down-regu-
lating expression of inositol transporter gene such as
sodium-myo-inositol transporter 1 (SMIT1) [4]. In sup-
port of the concept that inositol depletion may be the way
that lithium works in bipolar disorder and other CNS dis-
eases, inositol depletion mice due to the smit1 gene homo-
zygous deletion behave similarly to lithium-treated
animals [5]. However, much higher inositol depletion is
required for achievement of the behavioral effects in mice
than that achieved by lithium administration [6], suggest-
ing that the inositol depletion role of lithium is not
responsible for all its actions.
More and more studies suggest that inhibition of
GSK-3b may be a more relevant target for the patho-
physiology of bipolar disorder and the therapeutic action
of lithium [7]. For example, loss of GSK-3 function in
Xenopus and Dictyostelium results in developmental
abnormalities that are phenocopied by lithium treatment
[8,9]. More importantly, mice with heterozygous loss of
GSK-3b genotype exhibit behavioral and molecular
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changes similar to those induced by lithium treatment
[10], and transgenic mice overexpressing GSK-3b show
hyperactivity resembling that observed in the manic
phase of bipolar disorders [11]. In agreement with the
in vivo role of GSK-3b in inhibition of neural precursor
cell proliferation [12], GSK-3b inhibition is also involved
in lithium-mediated proliferation of human NT2 neural-
like precursor cells and proliferation recovery of dexa-
methasone-treated adult rat dentate gyrus-derived
neural precursor cells (ADP) [13,14].
GSK-3b is a serine/threonine kinase that has diverse
functions in various cellular activities in many cell types,
including glycogen synthesis, cell survival and cell divi-
sion [15]. Unlike most protein kinases, GSK-3b is con-
stitutively active and its activity is down-regulated by
upstream signals through inhibitory phosphorylation.
The most important and well-known target of GSK-3b
is the b-catenin transcriptional coactivator. Active GSK-
3b can directly phosphorylate b-catenin, resulting in
ubiquitination-medaited proteasomal degradation of b-
catenin. The NF-AT transcription factor has been found
to be another target of GSK-3b, at least in T cells and
neurons [16,17]. Different from the b-catenin phosphor-
ylation, NF-AT phosphorylation mediated by GSK-3b
promotes its export from the nucleus, therefore termi-
nating NF-AT-dependent transcription [18]. The NF-AT
activation is delicately counterbalanced by GSK-3b and
Ca2+-calcineurin. GSK-3b phosphorylates NF-AT, lead-
ing to its nuclear export and transcriptional inactivation,
while Ca2+-calcineurin dephosphorylates NF-AT, leading
to its nuclear import and transcriptional activation.
Currently, the two models have not been well reconciled
yet. Part of the reasons might be due to that the outcome
of lithium administration may be cell type dependent. In
the present study, we showed that lithium promoted pro-
liferation but not survival of neural precursor cells. Consis-
tently, we found that lithium specifically induced
expression of a subset of cell proliferation-related genes in
these cells. Whereas addition of inositol had no effect on
lithium-induced neural precursor cell growth, inhibition of
GSK-3b showed an effect similar to lithium. On the other
hand, inhibition of calcineurin/NF-AT antagonized the
effect of lithium on neural precursor cell proliferation.
Although lithium administration was able to increase inhi-
bitory phosphorylation of GSK-3b, it failed to stabilize b-
catenin. These studies suggested that targeting GSK-3b for
NF-AT activation is the main mechanism for lithium-
induced neural precursor cell proliferation.
Results
Lithium increases numbers of neural precursor cells in
culture
Given its clinical benefit on manic depressive illness and
its potential application for other central nervous system
diseases, we investigated the effects of lithium on growth
of neural precursor cell line RG3.6 cells as well as pri-
mary neural precursor cells isolated from neonatal
mouse and rat. As shown in Figure 1A, lithium chloride
(LiCl) treatment resulted in a dose-dependent cell num-
ber increase in RG3.6 cell cultures with the maximal
effect at 3 mM. In contrast, 3 mM sodium chloride
(NaCl) treatment had no obvious effect on RG3.6 cell
numbers (Figure 1B), indicating that the lithium, but
not the chloride, in LiCl was responsible for the cell
number increase. Similarly, lithium significantly induced
cell number increase in mouse and rat primary neural
precursor cell cultures (Figures 1C and 1D). These
results suggested a general role of lithium in cell num-
ber increase of various neural precursor cells.
Lithium has no significant effect on the survival of neural
precursor cells
To investigate the mechanism by which lithium induces
cell number increase of neural precursor cells, we analyzed
the effect of lithium on survival of RG3.6 cells. The RG3.6
cell line was originally derived from GFP transgenic rat
[19]. When these cells die, they lose their GFP signal, as
revealed by the mutual exclusiveness of GFP signal with
the red fluorescent signal due to propidium iodide stain-
ing, a hallmark of dead cells (Figure 2A). Therefore, GFP
expression in these cells provides a convenient marker for
survival cells. Accordingly, we performed flow cytometry
assay to compare the percentage of GFP-expressing live
cells in RG3.6 cell cultures treated with 3 mM LiCl or con-
trol NaCl. Surprisingly, LiCl treatment failed to increase
the ratio of survival cells, compared to NaCl treatment
(Figures 2B and 2C). Nevertheless, this result indicated
that lithium has no significant effect on neural precursor
cell survival, excluding the possible role of cell survival in
lithium-induced cell number increase.
Lithium promotes proliferation of neural precursor cells
The results above further suggest that lithium may pro-
mote proliferation of neural precursor cells, which
accounts for the lithium-induced cell number increase.
To verify this, we measured cell proliferation by per-
forming bromodeoxyuridine (BrdU) incorporation assay
to label dividing cells. In the NaCl control group, about
23% neural precursor cells were BrdU positive after 4
hours of BrdU incubation (Figure 3A and 3B). However,
the ratio of the BrdU positive cells was increased to 38%
in the group treated with LiCl. Together, these results
suggest that lithium stimulates proliferation, but not
survival, of neural precursor cells.
Lithium induces a subset of cell proliferation-related genes
To further confirm our finding above, we performed
microarray analysis to compare gene expression profiles in
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RG3.6 neural precursor cells treated with LiCl or control
NaCl. Consistent with our proliferation assay, many cell
proliferation-related genes were significantly up-regulated
upon lithium treatment (Additional file 1). Notably, none
of the known neurotrophic factors, such as NGFb, NGFg,
NT-3, BDNF, CNTF, GDNF and LIF, were induced by
lithium. Our real-time PCR using primary neural precur-
sor cells further demonstrated that lithium had no signifi-
cant effect on RNA expression of NGFb, NGFg, NT-3,
CNTF, GDNF and LIF (Figure 4). Thus, lithium-induced
increase in neural precursor cell numbers is mainly due to
lithium-induced stimulation of cell proliferation rather
than improvement of cell survival.
Myo-inositol has no significant effect on lithium-induced
proliferation of neural precursor cells
Since inositol depletion contributes to lithium action in
the central nervous system [5], we examined whether
addition of extracellular inositol blocks lithium-induced
neural precursor cell growth. As shown in Figure 5, up
to 10 mM of myo-inositol did not significantly affect
growth of RG3.6 cells during 5 days incubation. More
importantly, the same concentration of myo-inositol
failed to inhibit lithium-induced cell number increase.
This result suggests that inositol depletion is not the
mechanism by which lithium promotes neural precursor
cell proliferation.
Lithium-induced neural precursor cell proliferation
involves GSK-3b suppression
Lithium has been shown to inhibit glycogen synthase
kinase 3b (GSK-3b) activity in many types of cells
[8,20-24]. Thus, we examined whether GSK-3b inhibi-
tion is involved in lithium-induced proliferation of
neural precursor cells. First, we examined whether
lithium inhibits GSK-3b in neural precursor cells by
detecting phosphorylation levels of GSK-3b at serine 9
in the presence of LiCl or NaCl. Phosphorylation of this
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Figure 1 Lithium induced cell number increase in neural precursor cultures. (A) Lithium chloride dose dependently stimulated cell number
increase in RG3.6 cell cultures. Cell count analysis was performed on cultures of RG3.6 cells treated with the indicated doses of LiCl for 7 days. *:
Bonferroni/Dunn, P < 0.002 compared to no LiCl control. (B) Lithium chloride but not sodium chloride induced cell number increase in RG3.6
cell cultures. Cell count analysis was performed on cultures of RG3.6 cells treated with control medium, 3 mM NaCl or 3 mM LiCl for 5 days. *:
paired t test, P < 0.01 compared to 3 mM NaCl or control medium treatment. (C) Lithium stimulated cell number increase in rat primary neural
precursor cell cultures. Cell count analysis was performed on cultures of rat primary neural precursor cells treated with 3 mM NaCl or 3 mM LiCl
for 5 days. *: Bonferroni/Dunn, P < 0.002. (D) Lithium stimulated cell number increase in mouse primary neural precursor cell cultures. Cell count
analysis was performed on cultures of mouse primary neural precursor cells treated with 3 mM NaCl or 3 mM LiCl for 5 days. *: Bonferroni/Dunn,
P < 0.002. The data represent mean ± standard error (n = 6 for each condition).
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serine is one important mechanism leading to GSK-3b
inactivation. Consistent with its inhibitory role in other
cell types, lithium also significantly increased phosphor-
ylation of GSK-3b at serine 9 in RG3.6 cells (Figures 6A
and 6B). This result suggests that lithium suppresses
GSK-3b activity in neural precursor cells.
Next, we tested the potential effects of other GSK-3b
inhibitors on the proliferation of neural precursor cells.
If lithium-mediated suppression of GSK-3b plays a role
in neural precursor cell proliferation, other GSK-3b
inhibitors should have the effects similar to lithium on
RG3.6 cell growth. For this purpose, we utilized two
potent and specific GSK-3 inhibitors, SB216763 and
SB415286. Indeed, both SB216763 and SB415286 treat-
ments resulted in significant cell number increase, just
like lithium treatment (Figure 6C). Collectively, these
results suggest that inhibition of GSK-3b contributes to
lithium-induced neural precursor cell proliferation.
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Figure 2 Lithium had no significant effect on percentage of GFP expressing live cells in RG3.6 cell cultures. (A) GFP-expressing cells are
negative for propidium iodide (PI) staining. RG3.6 neurospheres were dissociated by trypsinization. The dissociated cells were stained with PI, a
red fluorescent nuclear dye that specifically stain dead cells. The green GFP signal and the red PI staining were visualized and photographed
using fluorescent microscope. (B) RG3.6 cells treated with NaCl or LiCl had similar GFP histograms. Flow cytometry analysis was performed on
RG3.6 cell cultures treated with 3 mM NaCl or 3 mM LiCl for 3 days. Cells grown in non-FGF2 containing medium for 6 days were used as a
negative control to gate GFP signal, since most cells grown in this condition were dead. (C) Quantification of the data shown in B. Lithium
treatment had no significant effect on the percentage of GFP-expressing live cells in RG3.6 cell cultures.
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Calcineurin/NF-AT inhibitor cyclosporin A antagonizes
lithium-induced neural precursor cell proliferation
To find GSK-3b downstream signaling involved in
lithium-induced neural precursor cell proliferation, we
analyzed b-catenin and NF-AT: two most important tar-
gets of GSK-3b. GSK-3b inhibits both b-catenin and
NF-AT by directly phosphorylating them. While GSK-
3b-mediated NF-AT phosphorylation results in its
retention in the cytoplasm, b-catenin phosphorylation
by GSK-3b leads to its proteasomal degradation. Thus,
we examined the effect of lithium treatment on b-cate-
nin protein stability and NF-AT subcellular expression
in RG3.6 neural precursor cells. As revealed by our
immunoblotting assays, lithium treatment had no
obvious effect on b-catenin protein expression (Figure
7A) but significantly increased nuclear translocation of
NF-AT (Figure 7B). Consistently, the lithium treatment
also led to the transcriptional activation of NF-AT (Fig-
ure 7C). This result suggests that NF-AT, but not b-
catenin, may be involved in lithium-induced prolifera-
tion of neural precursor cells.
GSK-3b-mediated inhibition of NF-AT is counterba-
lanced by Ca2+-calcineurin. Ca2+-calcineurin depho-
sphorylates and thereby activates NF-AT. To
investigate the role of NF-AT in lithium-induced pro-
liferation of neural precursor cells, we took advantage
of cyclosporin A (CsA), a specific inhibitor of the NF-
AT activator calcineurin. If NF-AT activation is
involved in lithium-induced proliferation of neural pre-
cursor cells, CsA should suppress the effect of lithium.
As shown in Figure 7D, CsA alone, at doses of up to 1
μM, did not significantly affect RG3.6 cell growth,
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Figure 3 Lithium significantly increased percentage of BrdU+
cells in RG3.6 cell cultures. RG3.6 cells were grown in culture
medium containing 3 mM LiCl or control NaCl on laminin-coated
coverslips for 3 days followed by 4 hours of BrdU labeling and
subsequent BrdU immuno-staining. The data represent mean ±
standard error. *: Bonferroni/Dunn, P < 0.0001, n = 8 for each
condition.
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Figure 4 Lithium had no significant effect on RNA expression
of neurotrophic factors CNTF, GDNF, LIF, NGFb, NGFg and NT-3
in rat primary neural precursor cells. Rat primary neural precursor
cells were treated with 3 mM LiCl or control NaCl for 3 days. Then
the cells were lysed for RNA extraction and subsequent quantitative
real time PCR analysis. RNA levels of neurotrophic factors were
normalized to peptidylprolyl isomerase A (Ppia). The data represent
mean ± standard error. *: Bonferroni/Dunn, P < 0.05, n = 3 for each
condition.
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Figure 5 Inositol had no significant effect on lithium-induced
cell number increase in RG3.6 cell cultures. Cell count analysis
was performed on RG3.6 cells cultured for 5 days in medium with
or without 3 mM LiCl, and with or without 1 mM or 10 mM myo-
inositol (n = 6 for each condition). The data represent mean ±
standard error, and significance was determined with Fisher’s PLSD
post hoc test following analysis of variance (ANOVA).
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although at doses of 10 μM or above it significantly
reduced RG3.6 cell numbers. More interestingly, CsA,
even at the low dose (1 μM) that does not affect cell
growth, completely abolished lithium-induced RG3.6
cell number increase (Figure 7E). Together, these
results suggest that lithium-induced proliferation of
neural precursor cells involves GSK-3b suppression
and subsequent NF-AT activation.
Discussion
Lithium is a standard medication for bipolar disorder.
Recent in vitro and animal studies suggest a great
potential of lithium in the treatment of other central
nervous system (CNS) diseases, although the involved
mechanisms remain elusive. Here, we have shown that
lithium promotes growth of neural precursor cells.
Lithium stimulates neural precursor cell proliferation
but not their survival. Our mechanistic studies further
indicate that lithium-induced neural precursor cell pro-
liferation involves the non-canonical GSK-3b-NF-AT
signaling, but not inositol depletion or b-catenin, the
canonical downstream signaling of GSK-3b.
Neurotrophic factors are well known for their roles in
neuron growth. Interestingly, it has been reported that
lithium induces expression of neurotrophic factors in
specific regions of rodent brain [25-30], although the
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Figure 6 Lithium inhibited GSK-3b in RG3.6 cells, and other GSK3b inhibitors mimicked lithium’s effect on RG3.6 cell growth. (A) RG3.6
cells were grown in culture medium containing 3 mM LiCl or 3 mM control NaCl for 3 days, followed by western blotting analysis on P-GSK-3b
(Ser9) and GSK-3b expression. (B) The blotting results in A were analyzed using ImageJ software (http://rsb.info.nih.gov/ij/, 1997-2007), and the
ratio of P-GSK-3b was plotted. (C) Other GSK-3b inhibitors, like lithium, also increased cell numbers in RG3.6 cell cultures. Cell count analysis was
performed on RG3.6 cells grown for 6 days in culture medium without or with 3 mM LiCl, 0.1% DMSO, 5 μM SB216763, or 25 μM SB415286 (n =
6 for each condition). DMSO was used as the vehicle control for SB216763 and SB415286, since these two drugs were dissolved in DMSO. The
data represent mean ± standard error, and significance was determined with Bonferroni/Dunn post hoc analysis following ANOVA.
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Figure 7 Calcineurin/NFAT inhibitor cyclosporin A antagonized lithium-induced cell number increase in RG3.6 cell cultures. (A) Lithium
did not significantly change b-catenin expression in RG3.6 cells. RG3.6 cells were grown for 3 days in culture medium containing 3 mM LiCl or 3
mM control NaCl. The cells were then lysed in RIPA for western blotting analysis on b-catenin and b-actin expression. (B) Lithium increased
nuclear expression of NF-AT. Aliquot of cells from A were used for cytoplamic and nuclear fractionation, followed by western blotting assays for
the subcellular expressions of NF-AT. (C) Lithium stimulated transcriptional activation of NF-AT. RG3.6 cells treated with LiCl or NaCl were used
for gene reporter assays. The luciferase activity is presented as fold induction relative to that of NaCl-treated cells. *: paired t test, P < 0.01. (D)
Effect of different doses of cyclosporin A (CsA) on RG3.6 cell growth. Cell count analysis was performed on RG3.6 cells grown for 5 days in
culture medium containing various doses of CsA (0 (Control), 0.01 μM, 0.1 μM, 1 μM, 10 μM, 50 μM, n = 6 for each dose). *: paired t test, P <
0.005 compared to control, 0.01 μM, 0.1 μM, or 1 μM CsA condition. (E) Cyclosporin A antagonized lithium-induced RG3.6 cell growth. Cell count
analysis was performed on RG3.6 cells grown for 5 days in culture medium with or without 3 mM LiCl, and with or without 1 μM CsA (n = 6 for
each condition). The data represent mean ± standard error. *: paired t test, P < 0.02 compared to No CsA + No LiCl, or CsA + No LiCl condition.
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resource cells for the neurotrophic factors and the exact
functions of their induction await investigation. One of
the potential resources is neurons, because lithium
increases neurotrophic factor expression in cultured cor-
tical neurons, which is essential for neuroprotection
under certain stress conditions [31]. However, lithium
failed to up-regulate neurotrophic factors in neural pre-
cursor cells (Figure 4 and Additional file 1), suggesting
that neural precursor cells are not additional resources
for the survival factors. Instead, lithium significantly
enhanced expression of numerous proliferation-related
genes (Additional file 1). In results consistent with the
gene induction profile, lithium only promoted prolifera-
tion but not survival of neural precursor cells (Figures 1,
2 and 3). These data were also consistent with the fact
that neurotrophic factors are not required for growth of
neural precursor cells, at least in vitro. These studies
together thus suggest that the effects of lithium are cell
type dependent.
Two different hypotheses have been proposed to
explain the lithium’s mood-stabilizing properties: inosi-
tol depletion and GSK-3 inhibition. However, it remains
obscure how these two hypotheses are integrated.
Although increasing evidence has suggested a relatively
more dominant role of GSK-3 inhibition in the actions
of lithium [7], it seems highly plausible that inositol
depletion and inhibition of GSK-3 both contribute to
the therapeutic actions of lithium; because either inosi-
tol depletion or GSK-3b deficient animals exhibit phe-
notypes the same as, although similar to, those induced
by lithium treatment [5,10]. Given the important role of
inositol in various signaling pathways including the
GSK-3 pathway and the essential role of GSK-3 in the
optimal de novo synthesis of inositol [32], the two dif-
ferent mechanisms possibly also together with other
mechanisms collaboratively fine-tune animal’s responses
to lithium.
It is likely that the relative importance of each
mechanism is also context dependent. For example,
insoitol depletion and GSK-3b inhibition are responsible
for lithium-induced growth cone spread in dorsal root
ganglion sensory neurons and neuronal polarity of hip-
pocampal neurons, respectively [26-35]. In the hippo-
campal neuron polarity, collapsin response mediator
protein-2 (CRMP-2), a factor critical for specifying
axon/dendrite fate by promoting neurite elongation via
microtubule assembly, is the major target of GSK-3b
[33]. Our studies here suggest that lithium stimulates
proliferation but not survival of neural precursor cells
(Figures 1, 2 and 3). Interestingly, inhibition of GSK-3b,
but not inositol depletion, is the mechanism accounting
for lithium-induced cell proliferation, because lithium
treatment led to GSK-3b inhibition and inhibition of
GSK-3b by other GSK-3 inhibitors showed an effect
similar to lithium (Figure 6). On the other hand, addi-
tion of myo-inositol had no effect on lithium-induced
neural precursor cell proliferation (Figure 5). We have
further found that NF-AT is the major downstream sig-
naling molecule of GSK-3b in lithium-induced neural
precursor cell proliferation, because inhibition of NF-AT
reversed the effect of lithium (Figure 7). The effect on
NF-AT seems highly specific, as lithium-mediated inhi-
bition of GSK-3b failed to stabilize b-catenin in the
same cells. Consistent with our studies, lithium also sti-
mulates proliferation of human NT2 neural precursor
cells but cannot stabilize b-catenin [16]. Paradoxically,
lithium recovers, rather than directly increases, the pro-
liferation of ADP rat neural precursor cells from dexa-
methasone-mediated inhibition [17]. The difference
could be due to the different sources of the neural pre-
cursor cells used. NT2 and RG3.6 cell lines were
embryonic as well as primary neural precursor cells we
used in this study were from neonatal animals. On the
other hand, ADP cells were from adult rat. Nevertheless,
these studies suggest that lithium utilizes different
mechanisms to achieve the same or different effect on
different cells. These effects are further integrated,
which will decide the final outcome of lithium adminis-
tration. Thus, understanding when and where each
mechanism is most effective will help to fine-tune thera-
peutic strategies to promote or constrain specific arms
of lithium.
Materials and methods
Antibodies and reagents
Anti-phospho-GSK-3b (Ser9) and anti-GSK-3b antibo-
dies were purchased from Cell Signaling. Anti-b-catenin
antibody was from BD Biosciences. Anti-NF-ATc anti-
body was from Santa Cruz Biotechnology. Anti-bromo-
deoxyuridine (BrdU) antibody was from
DakoCytomation. Fluorescent dye-conjugated secondary
antibodies and 4’, 6-Diamidino-2-phenylindole (DAPI)
were from Molecular Probes. Horse radish peroxidase-
linked anti-rabbit IgG was from Amersham Biosciences.
BrdU and myo-inositol were from Sigma-Aldrich. GSK-
3b inhibitors SB216763 and SB415286 were from Tocris
Cookson, Inc. Calcineurin inhibitor cyclosporin A was
from Sandoz Pharmaceuticals. EGF and FGF2 were
from BD Biosciences.
Primary neural precursor cell culture
Olfactory bulbs and subventricular zone tissue samples
dissected from neonatal animal brains were suspended
in 0.05% trypsin (Sigma-Aldrich), minced by sequentially
passing through 18-, 21- and 25-gauge needles, and
then incubated at 37°C for 5 minutes to dissociate the
cells. After adding an equal volume of trypsin inhibitor
(0.25 mg/ml, Sigma-Aldrich), the cells were further
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dissociated by pipetting up and down. After washed
twice with DMEM/F12 medium (Invitrogen), the cell
samples were re-suspended in growth medium, i.e.
DMEM/F12 supplemented with 25 mM glucose (Sigma-
Aldrich), 1X B27 (Invitrogen), 10 ng/ml FGF2 (BD Bios-
ciences) and 10 ng/ml EGF (BD Biosciences), filtered
through a 70 μm nylon mesh, and cultured at 37°C in a
humidified atmosphere of 95% air + 5% CO2. After 24
hrs of culturing, the cells were washed three times with
DMEM/F12 and pipetted up and down for dissociation
at each wash. The cells were then re-suspended in new
growth medium, filtered through a 40 μm nylon mesh
and incubated at 37°C in a humidified atmosphere of
95% air + 5% CO2. One-tenth of the growth medium
was replenished with DMEM/F12 supplemented with
100 ng/ml EGF, 100 ng/ml FGF2, and 1X B27 every
other day. For treatment, passage 3 neural precursor
cells were cultured in DMEM/F12 supplemented with
25 mM glucose (Sigma-Aldrich), 1X B27, 0.2 ng/ml
EGF, 0.2 ng/ml FGF2, in the presence of 3 mM lithium
chloride (LiCl) or 3 mM control sodium chloride (NaCl)
before the cultures were stopped for analysis.
RG3.6 cell culture
Rat neural precursor cell line RG3.6 was kindly provided
by Dr. Martin Grumet [19]. After passage, the RG3.6
cells were grown in culture medium, i.e. DMEM/F12
supplemented with 25 mM glucose, 1X B27, 0.2 ng/ml
FGF2, and 2 μg/ml heparin (Sigma-Aldrich), in the
absence or presence of various doses of LiCl or 3 mM
NaCl before the cultures were stopped for analysis.
Cell treatment and Cell count analysis
Cells were cultured in 96-well plates in growth medium
containing the indicated concentration of NaCl or LiCl
in the presence or absence of the indicated concentra-
tions of inositol, CsA, SB216763, SB415286, or mock
DMSO for the indicated time points as described
[4,14,17]. Quantification of cell number was done using
the Cyquant cell proliferation assay kit (Invitrogen)
according to the manufacturer’s protocol.
BrdU labeling and immunocytochemistry
RG3.6 neural precursor cells were grown for 3 days on
laminin (Invitrogen, 20 μg/ml)-coated coverslips in cul-
ture medium containing 3 mM LiCl or 3 mM control
NaCl. Then the cells were labeled with BrdU (10 μM)
for 4 hours, and then fixed with 4% para-formaldehyde
at room temperature for 15 minutes. The fixed cells
were treated with 2 M HCl for 30 minutes at room tem-
perature, followed by 3 times wash with borate buffer
(0.1 M, pH 8.5). Normal goat serum (NGS, Invitrogen,
2% in PBS-T, i.e. 0.01 M phosphate buffered saline with
0.05% Tween 20) was applied for 30 minutes to block
non-specific binding of antibodies. Mouse monoclonal
anti-BrdU antibody (DakoCytomation, 1:100 in PBS-T/
2% NGS), goat-anti-mouse AlexaFluor 546 (Molecular
Probes, 1:500 in PBS-T/2% NGS), and DAPI (4’,6-Dia-
midino-2-phenylindole, Molecular Probes, 1:1000 in
PBS-T/2% NGS) nuclear dye were sequentially applied
at room temperature for 30, 30 and 10 minutes, respec-
tively, with PBS-T washing for 3 times after each appli-
cation. After mounting the coverslips onto slides, the
fluorescent staining was visualized using fluorescent
microscope.
Flow cytometry
RG3.6 neurospheres formed after grown in culture med-
ium containing 3 mM NaCl or 3 mM LiCl for 3 days
were dissociated by treatment with trypsin-EDTA
(0.25% trypsin, 1 mM EDT•4Na, Invitrogen) for 3 to 5
minutes at room temperature, and pipetting up and
down after adding an equal volume of 0.25 mg/ml tryp-
sin inhibitor (Sigma-Aldrich). The cells were washed
twice with 1 × PBS (pH 7.4). Flow cytometry was per-
formed to analyze the GFP signals in the samples using
a flow cytometer as described previously [36].
Subcellular Fractionation and Western blotting
RG3.6 cells were grown in culture medium containing 3
mM NaCl or 3 mM LiCl for 3 days. Cells were lysed in
radioimmuoprecipitation assay buffer (RIPA buffer) [50
mM Tris-HCl pH7.4, 150 mM NaCl, 1 mM EDTA,
0.25% Na-deoxycholate, 1% NP-40, 1 mM dithiothreitol
(DTT), 1 mM phenylmethylsulfonyl fluoride (PMSF)]
supplemented with a protease inhibitor mixture for
whole lystes [37]. For cytoplasmic and nuclear extracts,
cells were first lysed in Buffer B (10 mM Hepes, pH 7.9,
10 mM KCl, 0.4% Nonidet P-40, 0.1 mM EDTA, 0.1
mM EGTA, 1 mM dithiothreitol, 1 mM phenylmethyl-
sulfonyl fluoride) followed by centrifugation for 5 min at
4°C and 12,000 × g. The supernatant was cytoplasmic
extract. The pellet (nucleus) was further lysed in Buffer
C (20 mM Hepes, pH 7.9, 0.4 M NaCl, 0.1 mM EDTA,
1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluor-
ide) [38]. The whole cell lysates, cytoplasmic extract and
nuclear extract were used for immunoblotting assays as
described previously [39].
Luciferase gene reporter assays
RG3.6 cells treated with LiCl or NaCl were transfected
with NF-AT firefly and TK renilla luciferase reporters.
At 40 hrs post-transfection, luciferase activity was mea-
sured as we described before [40].
Quantitative real time PCR
Total RNA was extracted from RG3.6 cells or primary
neural precusor cells grown for 3 days in culture
Qu et al. Cell & Bioscience 2011, 1:18
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medium containing 3 mM LiCl or 3 mM control NaCl,
and reverse transcribed into cDNA. Quantitative real
time PCR was performed as described previously [41].
The primer pairs specific for the genes are indicated in
Additional file 2.
Affymetrix microarray analysis
Total RNA was extracted from RG3.6 cells grown for 3
days in culture medium containing 3 mM LiCl or 3 mM
control NaCl (3 samples per condition). The integrity of
the RNAs was examined using the Agilent platform
(Agilent 2100 Bioanalyzer). Biotin-labeling of cDNA and
subsequent hybridization using GeneChip® Rat Genome
230 2.0 Array (Affymetrix) were carried out by the
Transcriptional Facility Shared Resource of the Cancer
Institute of New Jersey as described previously [42].
GeneSpring GX 9 software (Agilent) was used to screen
genes whose RNA expression was significantly altered
by lithium treatment.
Statistical Analysis
Data were reported as mean ± standard deviation (SD).
The ANOVA post hoc or Student’s t test was used to
assess significance of differences, and p values ≤ 0.05
and 0.01 were considered statistically significant and
highly statistically significant, respectively [43].
Additional material
Additional file 1: Proliferation-related genes significantly up-
regulated by lithium in RG3.6 cells. RG3.6 cells were treated with 3
mM LiCl or 3 mM control NaCl (3 samples per condition), followed by
RNA extraction and microarray analysis using the GeneChip®® Rat
Genome 230 2.0 Array (Affymetrix) GeneSpring GX 9 software (Agilent)
was used to screen genes whose RNA expression. Proliferation-related
genes that were significantly up-regulated two folds by lithium are listed.
Additional file 2: Primers used for real-time PCR. Primer sequences,
gene names and their gene bank access numbers are listed.
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